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Abstract
Although overall survival in diffuse large B cell lymphomas (DLBCL) has improved, central nervous system (CNS) relapse is
still a fatal complication of DLBCL. For this reason, CNS prophylaxis is recommended for patients at high risk of CNS disease.
However, no consensus exists on definition of high-risk patient and optimal CNS prophylaxis. Systemic high-dose methotrexate
in combination with R-CHOP has been suggested as a potential prophylactic method, since methotrexate penetrates the blood-
brain barrier and achieves high concentration in the CNS. In this retrospective analysis, we report treatment outcome of 95 high-
risk DLBCL/FL grade 3B patients treated with R-CHOP or its derivatives with (N = 57) or without (N = 38) CNS prophylaxis. At
a median follow-up time (51 months), CNS relapses were detected in twelve patients (12.6%). Ten out of twelve (83%) of CNS
events were confined to CNS system only. Median overall survival after CNS relapse was 9 months. Five-year isolated CNS
relapse rates were 5% in the prophylaxis group and 26% in the group without prophylaxis. These findings suggest that high-dose
methotrexate-containing prophylaxis decreases the risk of CNS failure.
Keywords Diffuse largeBcell lymphoma .Centralnervoussystemprophylaxis .High-dosemethotrexate .Centralnervoussystem
recurrence
Introduction
Diffuse large B cell lymphoma (DLBCL) is the most frequent
form of non-Hodgkin lymphoma, accounting for 25–58% of
all NHL cases [1, 2]. DLBCL is responsive to chemotherapy
and with current immunochemotherapy regimen, R-CHOP or
its derivatives, about 60% of patients achieve long-term dis-
ease-free survival [3–5]. The addition of rituximab (R) to cy-
clophosphamide, doxorubicin, vincristine and prednisolone
(CHOP) chemotherapy has improved the response rate and
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the overall survival in DLBCL patients. However, simulta-
neously with improving systemic disease control, solitary cen-
tral nervous system relapses have evolved as an increased
problem. Patients with disease progression into the CNS have
poor survival, despite aggressive interventions, with median
survival of about 2–5 months [6–8]. The incidence of CNS
recurrence varies from 5 to 25% in DLBCL [8–14]. After
facing this problem in Oulu University Hospital, we incorpo-
rated into our treatment algorithm an intravenous high-dose
methotrexate (MTX)-based CNS prophylaxis to patients at
high risk of CNS relapse according to evaluation by clinical
risk factors.
With this background, we report on a retrospective analysis
of 95 high-risk DLBCL patients treated with R-CHOP, R-
CEOP or R-CHOEP immunochemotherapy with or without
CNS prophylaxis during 2006–2012, mainly in Oulu
University Hospital. We compared these results with patients
with similar risk profile treated without MTX-containing pro-
phylaxis and who were either treated in other hospitals, with
different local treatment algorithms, or had contraindications
to systemic high-dose methotrexate. We report the incidence
and risk factors for CNS relapse and impact of CNS prophy-
laxis on CNS relapse rates.
Material and methods
Patients, staging and treatment
Patients had a high-risk DLBCL or follicular lymphoma grade
3B, were diagnosed between January 2006 and December
2012 and treated at our hospital, except for seven patients
treated in Kuopio University Hospital where the patients were
treated without CNS-targeted therapy in line with the local
protocol. Patients with human immunodeficiency virus
(HIV) or CNS involvement at diagnosis were excluded. Two
patients were excluded from the analyses due to decreased
general condition and death soon after the prephase therapy.
Baseline clinical characteristics including WHO perfor-
mance status (PS) between grades 0 and 4, routine chemistry
profiles, clinical stage with a whole-body computer tomogra-
phy (CT) and bonemarrow aspiration and biopsy, number and
type of extranodal site and International Prognostic Index
(IPI) and CNS-IPI scores were recorded [15, 16]. Stage was
defined in accordance with the Ann Arbor system [17]. The
histopathological samples were reviewed and if possible,
cases were subclassified as germinal centre B cell-like
(GCB) and non-GCB in accordance with the Hans algorithm
[18]. The retrospective study was performed according to the
Declaration of Helsinki and approved by the ethics committee
of Oulu University Hospital, Finland.
Of the 104 high-risk DLBCL patients and one FL grade 3B
patient diagnosed, 103 patients received at least one cycle of
R-CHOP or its derivatives with curative intent. Eight patients
(of 103) received only intrathecal methotrexate as CNS pro-
phylaxis and were excluded from the analysis. N = 27 (28%)
patients were treated with R-CHOP, n = 43 (45%) patients
received R-CEOP and 25 (26%) patients were treated with
R-CHOEP. Median number of cycles were correspondingly
R-CHOP, 7 (range 6–8); R-CEOP, 6 (range 1–8); and R-
CHOEP, 7 (range 5–9) cycles. The median follow-up time
was 49 (range 0–110) months.
CNS prophylaxis
The screening for CNS involvement at diagnosis was at the
discretion of the treating physician and was performed if the
patient had any neurological signs or symptoms. However, for
55% of the patients who received CNS prophylaxis, the lum-
bar puncture (LP) had been performed before the initiation of
systemic therapy. In this situation, CNS involvement was ex-
cluded by neuroimaging with magnetic resonance imaging
(MRI) of the brain or cerebrospinal fluid (CSF) examination
with cytology and/or flow cytometry. The high risk of CNS
relapse was defined by any of the following: high-risk
International Prognostic Index score (IPI) ≥ 3, elevated LDH
and more than one extranodal site or specific extranodal sites
being sinus, epidural, testicular and breast. We also calculated
CNS-IPI, consisting of the individual IPI factors and involve-
ment of renal and/or adrenal glands for a total of six factors.
In line with the treatment algorithm at Oulu University
Hospital, all high-risk patients were treated with CNS-
targeted therapy with high-dose methotrexate from 3 to
5 g/m2 simultaneously with MTX IT therapy on day 1
a f t e r R - CHOP o r i t s d e r i v a t i v e s i n f u s i o n .
Correspondingly, patients in Kuopio University Hospital
were treated with R-CHOP. In elderly patients, the dose of
i.v. methotrexate was according to the discretion of the
treating physician. The number of MTX cycles varied in
accordance with tolerability from 1 to 3 cycles, and were
t y p i c a l l y a d m i n i s t e r e d w i t h s y s t e m i c
immunochemotherapy cycles 1–3 or 2–4. The main reason
to combine CNS prophylaxis with cycle 2–4 was pre-
treatment thirdspace fluid as ascites. The HD-MTX dose
and sequence and the number of cycles were at the treating
physicians’ discretion.
Based on actualized or unfulfilled CNS prophylaxis, the
patients were separated into three risk groups corresponding
to the different strategies of CNS-targeted therapy (Table 1):
Group 1: Intravenous HD-MTX 3–5 g/m2 × 2–3 + ITMTX
12.5 mg × 2–3 and the minimum cumulative dose of MTX ≥
9 g/m2,
Group 2: Intravenous HD-MTX 1 – 3 g/m2 × 1–3 +MTX
12.5 mg IT × 1–3.
Group 3: Patients did not receive CNS-targeted therapy.
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Response evaluation and follow-up
The response was evaluated in accordance with the
International Working Group response criteria [19] and, after
2007, following the revised International Working Group re-
sponse criteria [20]. Response to therapy was evaluated after
four, six and eight courses and thereafter every three months
for two years (whole-body imaging twice a year) and then
every six months until five years from the treatment (whole-
body imaging once a year). Neuroimaging was only per-
formed for patients with neurological symptoms or deficits.
The diagnosis of CNS recurrence was confirmed by MRI and
by CSF cytology or flow cytometry. Simultaneous system
relapse was excluded by whole-body CT.
Statistics
The primary objective was to compare the rates of CNS recur-
rence between different treatment groups based on CNS-
targeted therapy. The secondary objective was to evaluate
overall survival and progression-free survival in the whole
study population. Categorical variable tests were performed
using two-sided Pearson chi-squared test or Fisher’s two-
sided exact test, when possible. Continuous variables were
analysed using the Mann-Whitney U test or Kruskal-Wallis
test. Survival analyses with corresponding p values were cal-
culated using the Kaplan-Meier method with the log-rank test.
Progression-free survival was calculated from the date of the
pathological diagnoses to date of disease progression, or death
or the last date of follow-up. Overall survival was calculated
from the date of pathological diagnosis to death or the last date
of follow-up. We calculated two different CNS relapse rates.
Five-year isolated CNS relapse rate included patients whose
systemic disease was under control, but they experienced an
isolated CNS relapse. CNS relapse rate included both isolated
CNS relapses and those occurring simultaneously with a sys-
temic relapse. CNS relapse-free survival was the time between
the diagnosis date and CNS relapse. CNS survival was calcu-
lated from the CNS relapse date to death due to disease
progression. Patients dying to systemic relapses were cen-
sored at the date of death. p values < 0.05 were considered
significant. Cox regression was used to investigate the effect
of several clinical factors on the risk of CNS relapse.
Results
Patient characteristics
The baseline demographic and clinical characteristics of all 95
patients are listed in Table 2. The male/female ratio was 1.2;
overall median age was 61 ± 14 years (range 20–90). Fifty-
three percent of patients had WHO ≥ 2 and the majority of
patients had advanced stage disease (97%). Fifty-four percent
of patients had B symptoms, 94% had IPI ≥ 3 and 48% of
patients had CNS-IPI 4–6. Fifty-seven percent of patients
had more than one extranodal site. Eighty-two percent of pa-
tients had an elevated LDH.
In our study population, there were four patients with tes-
ticular lymphoma. One of these patients received the treatment
as per group 1 and the rest of the patients were treated as per
group 2. After immunochemotherapy all these patients re-
ceived contralateral scrotal irradiation.
CNS prophylaxis
Fifty-seven patients (60%) received CNS prophylaxis. The
main reasons to treat without CNS prophylaxis or to modify
HD-MTX doses and frequencies were age, co-morbidities,
renal insufficiency and the treating hospital. LDH level
(p < 0.001) and age (p < 0.006) differed significantly between
the group of patients treated without CNS-targeted treatment
and the groups of patients who received CNS prophylaxis.
There were no significant differences in IPI scores, CNS-IPI
scores, B symptoms, WHO classification and extranodal sites
between the patients receiving prophylaxis or not.
Table 1 Three risk groups
corresponding to the different
strategies of CNS-targeted thera-
py, based on actualized or unful-
filled CNS prophylaxis
Prophylaxis group CNS prophylaxis regimen R-
CHOP
R-
CEOP
R-
CHOEP
Intravenous
HD-MTX
Intrathecal
MTX
1 (n = 43) 3–5 g/m2 × 2–3 12.5 mg × 2–3 10 13 20
2 (n = 14) 1–3 g/m2 × 1–3 12.5 mg × 1–3 1 11 2
3 (n = 38) None None 16 19 3
Median number of
cycles (and range)
7 (6–8) 6 (1–8) 7 (5–9)
R-CHOP, rituximab-cyclophosamide-doxorubicin-vincristine-prednisone; R-CEOP, rituximab-cyclophosamide-
epirubicin-prednisone; R-CHOEP, rituximab-cyclophosamide-doxorubicin-vincristine-etoposide-prednisone
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Systemic relapse and survival
Twenty-two patients (23%) had a systemic relapse and this
was diagnosed in a median time of 10 months. Median sur-
vival after the relapse was 12 months. The five-year OS in this
high-risk patient population was 80% and correspondingly
PFS was 63%. Five-year overall survival based on cell of
origin phenotype was 85% in the germinal centre B cell type
(GCB) group and 70% with activated B cell type.
Corresponding rates for PFS were 66% and 49% (Fig. 1 a
and b).
CNS relapse
During mean follow-up time of 49 months, twelve (12.6%)
CNS relapses were detected. Ten out of twelve (83%) of those
were isolated in CNS system only without systemic disease.
The 5-year rates of isolated CNS relapses were 5%, 10.0% and
26% (p = 0.034) in treatment groups 1, 2 and 3 respectively.
The median time to isolated CNS relapse was 8 months (5–
44months) and the median overall survival after isolated CNS
relapse was 7 months (Fig. 2).
When considering both isolated CNS relapses and those
occurring simultaneously with the systemic disease, the five-
year CNS relapse rates in treatment groups 1–3 were 8%, 55%
and 26% respectively (Figs. 3 and 4).
Clinicopathological factors, association with CNS
relapse
Five out of twelve of the patients with CNS relapse presented
with a leptomeningeal disease. Eleven out of twelve (92%) of
CNS relapse patients had a non-GC phenotype. None of the
patients with CNS relapse had a double hit genotype and 5/12
were presented with double expressor phenotype. None of the
testicular lymphoma patients developed isolated CNS relapse,
but one patient suffered a simultaneous late systemic and CNS
relapse (58 months after diagnosis).
Clinical factors associated with the risk of CNS relapse
were GC phenotype (p = 0.018) and CNS prophylaxis (p =
0.029). In multivariate analysis, GC phenotype and not receiv-
ing CNS prophylaxis retained their independent significance
(Table 3).
Discussion
Central nervous system recurrence is a rare, but often fatal
event in DLBCL. After CNS relapse, the median survival of
patients is only 2–5 months. CNS-targeted therapy is an im-
portant component of treatment strategy for high-risk DLBCL
patients in order to prevent this devastating complication. No
consensus exists on the optimal method of CNS prophylaxis
Table 2 Demographics and
clinical characteristics at baseline High-risk with prophylaxis
(n = 57, groups 1 and 2)
High-risk without prophylaxis
(n = 38, group 3)
p value
Male/female ratio 1.2 1.1 0.87
Mean age (SD)
Age < 60
59 (± 11)
49% (28)
70 (± 10)
21% (8)
0.006
Stage 0.034
1–2 4% (2) 3% (1)
3–4 96% (55) 97% (37)
WHO 0.40
0–1 51% (29) 42% (16)
2–4 49% (28) 58% (22)
Presence of B symptoms 46% (26) 66% (25) 0.27
IPI
0–2 11% (6) 0% (0)
3–5 89% (51) 100% (38)
CNS-IPI
0–1 5% (3) 0% (0)
2–3 44% (25) 47% (15)
4–6 51% (29) 53% (17)
Extranodal sites > 1 56% (32) 58% (22) 0.87
High serum LDH level 93% (53) 66% (25) 0.001
WHO, World Health Organization; IPI, International Prognostic Index; CNS-IPI, Central Nervous System
International Prognostic Index; LDH, lactate dehydrogenase; high LDH is defined as LDH over upper limit of
normal
1826 Ann Hematol (2020) 99:1823–1831
and how to define high-risk patients. In this retrospective anal-
ysis, we demonstrated that intravenous HD-MTX-containing
therapy decreased the risk of CNS recurrence by 81% in a
group of high-risk DLBCL patients.
The addition of rituximab to the CHOP regimen has im-
proved treatment outcomes in DLBCL patients but had no, or
only minor impact on the incidence of CNS relapse [21, 22].
The reported CNS relapse rate (5–25%) has a wide variation
due to differences in clinical risk factors, study populations,
accuracy of diagnostic tests and type of CNS-targeted prophy-
laxis [9]. The incidence of isolated CNS relapse in DLBCL
without any systemic recurrence varies from 1.1 to 10.4%
[23]. In this analysis, the isolated 5-year CNS relapse rate
was 5% in patients with the HD-MTX-containing regimen
versus 26% in patients without CNS prophylaxis. The latter
number is high compared with most other published data. We
find this reflects the high-risk characteristics of our lymphoma
population in northern Finland, as 60% of our DLBCL
patients present with high IPI characteristics (unpublished da-
ta from hospital registry).
The impact of etoposide in preventing CNS events is con-
troversial [24–26]. In our analysis, 25/95 (26%) patients were
treated with R-CHOEP and these patients were overrepresent-
ed in group 1. We cannot exclude the possibility that it might
have interfered with the decrease in the CNS relapse incidence
in this group.
CNS recurrence usually occurs within the first few months
following diagnosis, but during the rituximab era some studies
have reported that CNS relapses seem to appear later than
previously [27, 28]. In line with this in the present series,
median time to CNS relapse was 8 months (range 5–
44 months). It also seems that, compared with pre-rituximab
era, CNS relapses are more often parenchymal and isolated
without systemic involvement [23, 28, 29].
Because the incidence of CNS relapse is relatively low and
the toxicities of CNS prophylaxis are moderate, there is an
unmet clinical need to better delineate the patients at the
highest risk of CNS disease. At the moment, this selection is
performed based on clinical disease presentation [30, 31]
[11–13, 28, 32, 33]. IPI has remained the most commonly
used tool for risk stratification. Several risk-scoring systems,
which consider also some specific extra nodal involvements,
have also been suggested to determine high-risk patients [11,
16, 34]. In spite of clinical presentation, lymphoma biology
especially double hit genotype, non-GC phenotype or double
expressor phenotype increases the risk for CNS recurrence
[35–37]. In line with literature, also in the present work in
multivariate analysis, non-GC phenotype and not receiving
prophylaxis were independent predictors of CNS relapse.
In our study, the full CNS prophylaxis consisted of three
courses of HD-MTX 3–5 g/m2 with or without ITMTX every
three weeks on day 1 of chemoimmunotherapy cycles 1–3 or
2–4. We found a remarkable difference of the CNS relapse
incidence rates between the patients treated with CNS-
targeted therapy compared with patients without prophylaxis.
Fig. 1 a Progression-free survival (PFS) (p = 0.044) and b five-year overall survival (OS) according to GC phenotypes: GCB in red and non-GC
phenotype in blue
Fig. 2 Kaplan-Meier estimate of overall survival (OS) of the patient after
the detection of central nervous system (CNS) relapse
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In the full prophylaxis group, hazard ratio was 0.22. It seemed
that CNS risk decreased also in the intermediate group albeit
less than in the full prophylaxis group.
There is a growing evidence supporting the use of high-dose
MTX as a CNS prophylaxis in DLBCL [38, 39]. Abrahamson
et al. reported in a retrospective study significant reduction in
the risk of CNS relapse with a median of three cycles of i.v.
methotrexate 3.5 g/m2 administered to high-risk patients. At a
median follow-up of 33 months, the incidence of CNS relapses
was only 3% in the high-risk population [40]. Ferreri et al.
reported a retrospective analysis of risk-tailored CNS prophy-
laxis in 200 DLBCL patients. One hundred seven out of two
hundred patients presented with high CNS relapse risk. Thirty-
three of these high-risk patients received i.v. HD-MTX prophy-
laxis with or without IT liposomal cytarabine and seven pa-
tients were treated only with IT. This therapy was associated
with a remarkable reduction in CNS relapse rates [41].
There is also prospective data supporting this hypothesis. In a
prospective Nordic phase II study (CRY-04), patients less than
65 years old with age-adjusted IPI 2 or 3 received six courses of
R-CHOEP14 followed by one course of high-dose cytarabine
(HD-Ara-C) and one course of HD-MTX, which resulted in a
CNS relapse rate of 4.5% [25]. Most CNS relapses were detect-
ed already during chemoimmunotherapy before the planned
CNS prophylaxis. For this reason in the subsequent Nordic
phase II study (CHIC), systemic CNS prophylaxis with HD-
MTX was given from the beginning of the therapy and CNS-
targeted therapy was further intensified by intrathecally admin-
istered liposomal Ara-C. To date, interim analysis has shown 3/
140 CNS relapses in a median follow-up time of 30 months
(ASH abstracts 2016; dose-dense chemoimmunotherapy includ-
ing early CNS prophylaxis for high-risk DLBCL. The final
analysis from a Nordic phase II study (CHIC-trial) is pending).
This prospective data supports the idea that delaying the CNS
prophylaxis until after completing chemotherapy may result in
increased CNS relapse rate [6, 42].
No consensus exists about the optimal HD-MTX dosing and
frequency. But MTX at a dose of 3 g/m2 as 4–6 h infusion
seems optimal in achieving effective concentrations and
avoiding serious toxicities [43, 44]. Although some studies
support some efficacy of IT chemotherapy, several others have
questioned its ability to prevent CNS dissemination [45, 46].
Fig. 3 Kaplan-Meier estimate of
isolated central nervous system
(CNS) relapse rate based on pro-
phylaxis group. Full prophylaxis
group in blue, inadequate pro-
phylaxis groups in red and no
prophylaxis group in green
Fig. 4 Five-year isolated CNS
relapse rates based on actualized
prophylaxis (p = 0.016). Full and
inadequate prophylaxis group in
blue and no prophylaxis group in
red
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This is a retrospective study with all the limitations and
pitfalls of this setting. There were differences between patient
groups in terms of age and the chemotherapy regimen select-
ed, which may have influenced our results. However, age lost
its independent prognostic value in multivariate analyses.
Despite these facts, we find that our study, together with other
existing data in the literature, supports the idea that high-dose
methotrexate-based CNS prophylaxis is associated with a sig-
nificant reduction in CNS relapse rates. We recommend that it
should be considered in DLBCL patients at high risk for CNS
recurrence. At the moment, we cannot draw definitive conclu-
sions about the optimal number of MTX courses. Further in-
vestigations are necessary to better understand the optimal
dose, quantity and timing of high-dose systemic methotrexate
required to achieve optimal prophylaxis and the possible ad-
ditional effect of IT MTX. Randomized clinical trials and
prospective studies are required to confirm these findings.
Also there is a need for finding better prognostic models,
biological factors or imaging techniques to define the real
high-risk patient population.
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